Diflucortolone valerate loaded solid lipid nanoparticles as a semisolid topical delivery system  by Abdel-Salam, Fatma S. et al.
Bulletin of Faculty of Pharmacy, Cairo University (2016) 54, 1–7Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLEDiflucortolone valerate loaded solid lipid
nanoparticles as a semisolid topical delivery system* Corresponding author. Tel.: +20 1007959631; fax: +20 2
27921305.
E-mail address: fatma.sami@ymail.com (F.S. Abdel-Salam).
Peer review under responsibility of Faculty of Pharmacy, Cairo
University.
http://dx.doi.org/10.1016/j.bfopcu.2015.11.002
1110-0931  2015 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.Fatma S. Abdel-Salam a,*, Seham A. Elkheshen b,c, Azza A. Mahmoud c,d,
Hussein O. Ammar c,daEgyptian Patent Office, Academy of Research and Technology, Cairo, Egypt
bDepartment of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt
cDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical
Industries, Future University in Egypt, Cairo, Egypt
dDepartment of Pharmaceutical Technology, National Research Center, Dokki, Cairo, EgyptReceived 30 June 2015; revised 7 September 2015; accepted 25 November 2015
Available online 23 December 2015KEYWORDS
Topical;
High shear homogenization;
Corticosteroid;
Diﬂucortolone valerate;
Solid lipid nanoparticlesAbstract Solid lipid nanoparticles (SLNs) are promising delivery carriers that have been utilized
for formulation and delivery of various drugs. For topical administration, they are usually incorpo-
rated into gel or cream to increase their residence time, which is time-consuming process and could
affect their stability and characteristics. Preparation of solid lipid nanoparticles based semisolid
formulations could have potential pharmaceutical applications. The aim of this study was to formu-
late the corticosteroidal drug, diﬂucortolone valerate (DFV) into topical semisolid SLN formula-
tions using a rapid cheap one-step process. SLN formulations were developed using a high-shear
homogenization combined with sonication, using different types of solid lipids (e.g., Geleol, Pre-
cirol ATO5, Tristearin and Compritol 888ATO) and Poloxamer 407 as a surfactant. Selection
of the lipids and using high lipid concentration were the key elements to get semisolid formulation
immediately after sonication without incorporating the nanoparticles into a gel or a cream base.
DFV SLN formulations possessed average particle size ranging from 203.71 ± 5.61 to 1421.00
± 16.32 nm with a narrow size distribution and possessed shear thinning behavior. Incorporation
of lipid based surfactants (Labrasol or Labraﬁl) was found to signiﬁcantly increase DFV
encapsulation efﬁciency (up to 45.79 ± 4.40%).
Semisolid DFV-loaded SLN with high drug encapsulation efﬁciency and acceptable rheological
behavior for topical preparation could be prepared in a one-step process.
 2015 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Solid lipid nanoparticles (SLNs) are the ﬁrst generation
colloidal drug carrier systems developed at the beginning of
the 1990s.1 SLNs are similar to nanoemulsions, although liquid
lipids used in emulsions are replaced by solid lipids, such as,
2 F.S. Abdel-Salam et al.glycerides or waxes.2 In particular, SLNs are suitable for topical
drug delivery, due to their ability to reduce skin irritation, pro-
tect the encapsulated active ingredients and allow for controlled
release of the drugs.3 In addition, they are well-suited for
inﬂamed skin because they are composed of physiologically tol-
erated lipids.4 Usually, lipid nanoparticle dispersions are incor-
porated into commonly used dermal carriers (e.g., gels or
creams) to obtain semisolid formulations. This multiple step
production process is time-consuming, and incompatibilities
between nanoparticles and gel or cream components may
occur.5,6 To overcome the previously mentioned challenges,
we applied a one-step process to produce semisolid SLN formu-
lations, using the high-shear homogenization and ultrasonica-
tion techniques.5,6
Topical corticosteroids are widely used for the treatment of
skin disorders that require anti-inﬂammatory and immunosup-
pressive regimens.7 They alleviate inﬂammation by inhibiting
vasodilatation and increasing vascular permeability that
occurs following inﬂammation, and they also decrease leuko-
cyte emigration into inﬂamed sites.8 Immunosuppressive corti-
costeroids reduce the response to delayed and immediate
hypersensitivity reactions by inhibiting the toxic effect of anti-
gen–antibody complexes that precipitate in vessel walls creat-
ing cutaneous allergic vasculities.9
Diﬂucortolone valerate (DFV) is a potent corticosteroid
esteriﬁed with valeric acid.10 It is insoluble in water, freely sol-
uble in dichloromethane, 1,4-dioxane, slightly soluble in
methanol, and sparingly soluble in ether. It is commercially
available in the form of 0.1 and 0.3% cream, oily cream and
ointment.11 DFV is characterized by rapid onset of action
and good tolerability in the treatment of cutaneous diseases12
such as, eczema, psoriasis, and discoid lupus erythematosus.
Hence, development of lipid nanoparticles that can be
loaded with the lipophilic drug, DFV, and applied topically as
semisolid formulations could be promising in the treatment of
several skin disorders. In addition, simpliﬁcation of the prepa-
ration procedures will be extremely useful for scale-up of vari-
ous pharmaceutical products which are based on these kinds
of nanoparticles. Therefore, the aim of this work was the prepa-
ration of SLNs semisolid formulations with acceptable rheolog-
ical properties, small particle size and low polydispersity index,
in addition to high drug entrapment efﬁciency, using high-shear
homogenization and ultrasonication techniques.
2. Materials and methods
2.1. Materials
Diﬂucortolone valerate (DFV) was purchased from Chemical
Industries Development (CID) (El Ahram, Giza, Egypt) which
was obtained from Bayer Schering Pharma, Germany. Geleol
(glyceryl monostearate 40–55%), Precirol ATO5 (glyceryl
distearate), Compritol 888 ATO (glyceryl behenate),
CapryolTM 90 (propylene glycol monocaprylate), Labrasol
(caprylocaproyl macrogol-8 glycerides EP) and Labraﬁl
(oleoyl macrogol-6 glycerides EP) were kindly donated by Gat-
tefosse0 (St Priest, Cedex, France). Tristearin (glyceryl tris-
tearate), Poloxamer 407 (pluronic F-127; a triblock
copolymer of polyoxyethylene–polyoxypropylene) were pur-
chased from Sigma Chemical Company (St. Louis, USA)
and methanol used was of analytical reagent grade.2.2. Preparation of diflucortolone valerate solid lipid
nanoparticles
Blank and drug loaded solid lipid nanoparticles were prepared
following the one step production method, as previously
reported.5,6 Brieﬂy, solid lipid was melted at 10 C above its
melting point, then, DFV was dispersed in the melted lipid.
The melted lipid phase was dispersed in the hot surfactant
solution (Poloxamer 407, 10% w/w) using high-shear homog-
enizer (Silent crusher homogenizer, Heidolph Instrument, Sch-
wabach, Germany) at 26,000 rpm for 5 min at 70 C, keeping
hot condition during the process using a water bath. This
o/w pre-emulsion was sonicated for 10 min using digital ultra-
sonicator (Model SH150-4L, MTI Corporation, California,
USA) maintaining temperature 10 C above the melting point
of the lipid, and the cycle was repeated twice. The produced
DFV dispersion was left to cool at room temperature.
2.3. Modification of diflucortolone valerate-loaded solid lipid
nanoparticles using lipid-based surfactants
Modiﬁed SLN formulations were prepared using lipid-based
surfactant aiming at increasing the solubility of the drug in
the lipid phase, and hence increasing its EE%. The added per-
centage of lipid-based surfactant replaced an equal amount of
the water content of each formula. Two lipid-based surfactants
were investigated, namely, Labrasol and Labraﬁl. Each of
them was tested at three concentration levels of 2.5, 5 and
10% w/w. DFV was dissolved in the lipid-based surfactant
prior to the addition of the solid lipid then the mixture was
heated to 10 C above the lipid melting point. The drug lipid
mixture was dispersed in an aqueous surfactant solution at
the same temperature and then the high-shear homogenization
and ultrasonication techniques were proceeded, as previously
explained.
2.4. Characterization of DFV-loaded solid lipid nanoparticles
2.4.1. Particle size analysis
Mean particle size and polydispersity index (PDI), which is a
measure of the distribution of nanoparticles population, were
determined using Zetasizer Nano ZS (Malvern instruments,
UK). Samples were prepared by diluting 0.2 g of the semisolid
preparation with 10 ml distilled water, then, vortexed for 30 s
and subsequently analyzed. Each sample was measured thrice.
2.4.2. Rheological studies
The rheological measurements were performed with a plate
and plate rheometer (Anton Paar GmbH, Ostﬁldern,
Germany). Up and down portions of the ﬂow curves were
determined using parallel plate geometry (50 mm diameter),
where, the gap between the two plates was 1 mm. About
0.5 g of the tested formulation was applied to the plate and left
until the temperature of the plate reached 25 ± 1 C. The mea-
surements were made over the whole range of speeding setting
from 0.5 to 350 rpm with 20 s between each two successive
speeds. The rheological behavior of each formulation was eval-
uated by plotting the shear stress versus the obtained shear rate
values. The ﬂow behavior was studied according to Farrow’s
equation13:
Table 1 Composition of solid lipid nanoparticles containing
0.1% w/w diﬂucortolone valerate.
Formulationa Lipid Poloxamer 407
concentration (%
w/w)
Type Concentration
(% w/w)
SLN1 Geleol 10 2.5
SLN2 10 5.0
SLN3 10 10.0
SLN4 20 2.5
SLN5 20 5.0
SLN6 20 10.0
SLN7 Precirol 10 2.5
SLN8 10 5.0
SLN9 10 10.0
SLN10 20 2.5
SLN11 20 5.0
SLN12 20 10.0
SLN13 Tristearin 10 2.5
SLN14 10 5.0
SLN15 10 10.0
SLN16 20 2.5
SLN17 20 5.0
SLN18 20 10.0
SLN19 Compritol 10 2.5
SLN20 10 5.0
SLN21 10 10.0
SLN22 20 2.5
SLN23 20 5.0
SLN24 20 10.0
a Formulation weight was made up to 100% with distilled water.
Diﬂucortolone valerate loaded solid lipid nanoparticles 3LogD ¼ N LogS Logg
where, D is the shear rate (s1), S is the shear stress (Pa), N is
Farrow’s constant and g is the viscosity (Pa s).
N is the slope of the plot of logD against logS, which indi-
cates the deviation from Newtonian ﬂow. When N is less than
one, it indicates dilatant ﬂow (shear rate thickening). If N is
greater than one, it indicates pseudoplastic or plastic ﬂow
(shear rate thinning). When the system showed thixotropic
behavior, the hysteresis area (H.A.) between the upward and
downward curves was measured adopting the trapezoidal rule.
Farrow’s constant was also calculated.
2.4.3. Determination of the entrapment efficiency
The entrapment efﬁciency (EE%) which corresponds to the
encapsulation of the drug into the nanoparticles was deter-
mined by measuring the concentration of free DFV in the dis-
persion medium. The dispersion of 0.2 g of each DFV loaded
sample in 5 ml methanol was vortexed for 30 s. Samples were
then centrifuged for 5 min at 9000 rpm and 5 C (Union
32R, Hanil Science Industrial, Korea) to extract the free drug
from the semisolid samples. The supernatant was collected and
ﬁltered through Milliporemembrane ﬁlter (0.2 lm) then mea-
sured spectrophotometrically at kmax 238 nm against blank
that was prepared using the same ingredients and the same
technique used in the preparation of the test formulations
but without the drug. The entrapment efﬁciency was calculated
as follows:
EE ð% w=wÞ ¼ ½ðWaWsÞ=Wa  100
where, Wa stands for the mass of DFV added to the formula-
tion and Ws is the mass of DFV determined in the
supernatant.
2.4.4. Scanning electron microscopy (SEM)
Prior to examination, samples were mounted on an aluminum
stub using a double sided adhesive tape and were made electri-
cally conductive by coating with a thin layer of gold (approx-
imately 20 nm) under vacuum. The scanning electron
microscope Jeol (Jxa-840A, Japan) was operated at an acceler-
ation voltage of 1000 kV and a magniﬁcation of 2500.3. Results and discussion
3.1. Preparation of diflucortolone valerate-loaded solid lipid
nanoparticles
Trials were carried out to prepare semisolid DFV loaded SLN
formulations, using different solid lipids (Geleol, Precirol
ATO5, Tristearin and Compritol 888 ATO). Table 1 repre-
sents different formulation, in which solid lipids were incorpo-
rated at two concentration levels of 10 and 20% w/w and
Poloxamer 407 was used as a surfactant at different concentra-
tions of 2.5, 5 and 10% w/w.
3.2. Characterization of DFV-loaded solid lipid nanoparticles
3.2.1. Particle size analysis
The results in Table 2 clearly show gradual decrease in particle
size upon increasing Poloxamer 407 concentration from 2.5
to 5 then to 10% w/w. This was in accordance with the factthat surfactant decreases the surface tension at the interface
of the particles which cause portioning of the particles and
hence formation of stabilized nanoparticles of smaller size
and higher surface area.14
SLN formulations that contain 10% w/w Precirol, Tris-
tearin and Compritol were not examined, as they resulted
in liquid dispersions and failed to show semisolid consistency.
However, formulations containing 10% w/w Geleol had
semisolid appearance after cooling. This occurred due to the
high concentration of monoglycerides in Geleol composition
that can form hydrogen bonds with water molecules, and thus
causing swelling. The swelling property is likely to form the
semisolid appearance of Geleol based formulations, even in
the presence low Geleol concentration.15
Comparing the particle size of the SLNs prepared with 20%
w/w solid lipids, Compritol-based SLNs exhibited the largest
particle size with all Poloxamer 407 concentrations, followed
by Geleol, then Tristearin, and ﬁnally Precirol that exhib-
ited the smallest particle size and PDI. A possible explanation
for the large particle size of Compritol-based SLNs may be
due to its high melting point (65–77 C) and the long hydrocar-
bon chain of behenic acid (C22) which represents 85% of the
acids esterifying glycerol in Compritol. High melting point
results in an increase in the viscosity and leads to an inefﬁcient
homogenization which causes an inefﬁcient reduction of the
particle sizes. Furthermore, the long hydrocarbon chains
(HC) of behenic acid (C22) in Compritol
 resulted in bulkier
molecules that are less susceptible to packaging into small size
particulates.16
Table 2 Mean particle size and polydispersity index-values of
0.1% w/w diﬂucortolone valerate loaded solid lipid
nanoparticles.
Formulation Mean particle size (nm)a PDIa
SLN1 593.70 ± 36.12 0.600 ± 0.066
SLN2 485.15 ± 13.22 0.455 ± 0.042
SLN3 296.90 ± 20.12 0.438 ± 0.120
SLN4 445.40 ± 15.92 0.419 ± 0.095
SLN5 426.90 ± 10.43 0.507 ± 0.083
SLN6 398.50 ± 17.65 0.509 ± 0.099
SLN7 ND ND
SLN8 ND ND
SLN9 ND ND
SLN10 531.70 ± 14.33 0.500 ± 0.100
SLN11 216.00 ± 30.26 0.203 ± 0.066
SLN12 203.71 ± 5.61 0.210 ± 0.070
SLN13 ND ND
SLN14 ND ND
SLN15 ND ND
SLN16 ND ND
SLN17 262.90 ± 29.40 0.365 ± 0.055
SLN18 271.15 ± 20.32 0.370 ± 0.062
SLN19 ND ND
SLN20 ND ND
SLN21 ND ND
SLN22 1421.00 ± 16.32 0.316 ± 0.150
SLN23 1344.01 ± 25.50 0.770 ± 0.090
SLN24 1012.04 ± 28.95 1.000 ± 0.030
ND: not determined.
a Values represent (mean ± SD).
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of Precirol and Tristearin. This may be due to the high con-
tent of monoglyceride in Geleol, which resulted in a higher
degree of interaction between the monoglyceride molecules
with water, causing swelling and an increase in viscosity parti-
cle size. Similarly, Jensen et al. found that the size of the SLN
increases as the monoglyceride content of the lipids increases.15
As mentioned previously, the hydrocarbon chain length of
lipids has a great inﬂuence on the particle size. Tristearin pos-
sesses a long hydrocarbon chain length of 57 carbon atoms
(C57) compared to the 39 carbon atoms (C39) of Precirol
.
As a result, Tristearin-based SLNs exhibited larger particle
size than that of Precirol-based SLNs. The higher molecular
weight of Tristearin compared to Precirol (891.48 and
625.02 g/mol, respectively) led to lower packaging efﬁciency
of the lipid molecules in the SLNs and larger particle size.
The higher the molecular weight of solid lipid, the greater
the particle size of the formed nanoparticles.17
3.2.2. Rheological studies
The rheological behavior of the prepared SLN formulations
was studied to determine the appropriate lipid type and con-
centration that can form semisolid matrices in a single-step
process. The rheological data namely Farrow’s constant (N)
and the hysteresis area (H.A.) for the selected SLN formula-
tions reveal that the semisolid SLN formulations exhibited
Farrow’s constant (n) values larger than one, which indicates
shear thinning characteristics with variable thixotropy (data
are not shown). The yield values for the investigated semisolid
SLN formulations were greater than 20 Pa. Products with yieldpoints below this value will ﬂow readily by themselves. A
lotion or cream with yield value above 20 Pa will ﬂow more
slowly.18
The combined shear thinning behavior and thixotropy are
desirable characteristics for topical formulations, as they facil-
itate processing during manufacture and the ﬂow from the
container, and improve spreading on the skin. In addition,
the applied ﬁlm can gain viscosity instantaneously and thus
resist running.19
3.2.3. Determination of entrapment efficiency
None of the prepared SLNs showed measurable entrapment of
DFV probably due to the low solubility of DFV in a wide
array of solid lipids, in spite of its lipophilicity. Moreover,
when the dispersion is performed above the lipid melting point,
an exchange of drug substance between lipid and aqueous
phase may occur during processing.15 Upon increasing the
temperature, the hydrophilic chains of the copolymer of
the surfactant (Poloxamer 407) were desolvated due to the
breakage of the hydrogen bonds that were established between
water and these chains. This phenomenon favors the
hydrophobic interactions among the polyoxyethylene domains
and leads to gel formation which is micellar in nature and has
solubilizing properties.20
Formulations prepared with 20% w/w Precirol and 5 and
10% w/w Poloxamer 407 (SLN11 and SLN12, respectively),
as well as, those prepared with 20% w/w Tristearin and 5
and 10% w/w Poloxamer 407, (SLN17 and SLN18, respec-
tively), showed the smallest size values of the formed particles
(216.0 ± 30.26, 203.7 ± 5.60, 262.9 ± 29.4 and 271.15
± 20.32 nm, respectively), and PDI values (0.203 ± 0.066,
0.210 ± 0.070, 0.365 ± 0.055 and 0.370 ± 0.062,
respectively).
SLN11 had a low viscosity and small hysteresis loop, and
thus indicating a low thixotropic behavior that may prevent
sticking on the skin for sufﬁcient time after application.21
SLN17 showed poor physical stability as a semisolid consistency
was found immediately after preparation that became harder
with ﬂake-like appearance after a few hours. This may be due
to the low concentration of Poloxamer 407 (5% w/w) that
was insufﬁcient to emulsify all the Tristearin, leading to inter-
actions between the glyceryl tristearate and water. Tristearin
(triglycerides) can be broken apart with water (hydrolysis) and
produce stearic acid of the high melting point (70 C).22 There-
fore, SLN12 and SLN18 were selected for further modiﬁcations
aiming at enhancing their entrapment efﬁciency.
3.2.4. Modification of 0.1% w/w diflucortolone valerate-loaded
solid lipid nanoparticles using lipid based surfactants
Modiﬁed SLN formulations were formulated using caprylo-
caproyl polyoxylglycerides (Labrasol) and oleoyl polyoxyl-
glycerides (Labraﬁl M1994CS) at concentrations of 2.5, 5
and 10% w/w (Table 3).
3.3. Characterization of modified 0.1% w/w diflucortolone
valerate loaded solid lipid nanoparticles
3.3.1. Particle size analysis
Table 4 represents the mean particle size and PDI values of
modiﬁed DFV-loaded Precirol and Tristearin SLN
formulations. The mean particle size of SLNs ranged from
Table 3 Composition of modiﬁed solid lipid nanoparticles containing 0.1% w/w diﬂucortolone valerate.
Formulationa Lipid Poloxamer 407 concentration
(% w/w/formula)
Lipid based surfactant
Type Concentration
(% w/w/formula)
Type Concentration (% w/w/formula)
SLN12A Precirol 20 10 Labrasol 2.5
SLN12B 20 10 5.0
SLN12C 20 10 10.0
SLN12D 20 10 Labraﬁl 2.5
SLN12E 20 10 5.0
SLN12F 20 10 10.0
SLN18A Tristearin 20 10 Labrasol 2.5
SLN18B 20 10 5.0
SLN18C 20 10 10.0
SLN18D 20 10 Labraﬁl 2.5
SLN18E 20 10 5.0
SLN18F 20 10 10.0
a Formulation weight was made up to 100% with distilled water.
Diﬂucortolone valerate loaded solid lipid nanoparticles 5188.7 ± 17.82 to 457.3 ± 21.33 nm and PDI ranged from
0.251 ± 0.12 to 0.405 ± 0.07. Results reveal that gradual
increase in Labrasol concentration in Precirol containing
SLNs, resulted in a signiﬁcant increase in particle size
(p< 0.05). This may be due to the hydrophilic properties of
Labrasol of HLB value of 14, which allowed partitioning in
the aqueous phase and failed to reduce the size of particles.
The size of Tristearin SLN formulations modiﬁed with
Labrasol at concentrations of 2.5, 5 and 10% w/w (SLN18A,
SLN18B and SLN18C, respectively) were not measured due to
the hard solid consistency that was formed upon cooling. This
may be due to the transformation of a or b0 polymorphic form
of Tristearin to the b form upon cooling. The a and b0 poly-
morphic forms of triacylglycerols are more desirable than the b
form because they have better appearance, texture and ﬂuidity.
The b form may give rise to rough or sandy texture. Unfortu-
nately, a or b0 forms are thermodynamically unstable and are
prone to transform to the more stable but undesirable b
form.23 These results were further investigated by examining
SLN18C using a scanning electron microscope. Fig. 1 shows
the rough and porous surface of SLN18C, which may be due
to the formation of the b form of Tristearin after cooling,
with the undesirable rough texture. Tristearin SLNs modiﬁedTable 4 Mean particle size and polydispersity index of modiﬁed 0.
Formulation Mean particle size (nm)a
SLN12A 201.8 ± 14.50
SLN12B 240.6 ± 11.32
SLN12C 447.7 ± 15.11
SLN12D 188.7 ± 17.82
SLN12E 195.1 ± 20.05
SLN12F 211.7 ± 13.44
SLN18A ND
SLN18B ND
SLN18C ND
SLN18D 457.3 ± 21.33
SLN18E 323.2 ± 25.42
SLN18F 245.2 ± 18.31
ND: not determined.
a Values represent (mean ± SD).with Labraﬁl did not show this rough texture probably due to
the lipophilic properties of Labraﬁl with HLB value of 4,
which increases its miscibility in Tristearin, and thus leading
to stabilization of the polymorphic form of Tristearin in the
desired a or b0 forms.
The mean particle size was not signiﬁcantly (p> 0.05)
affected by the gradual increase of Labraﬁl concentration
in Precirol SLN formulations. However, Tristearin SLN
formulations modiﬁed with Labraﬁl showed a signiﬁcant
decrease in particle size upon increasing Labraﬁl concentra-
tion from 2.5 to 5 and to 10% w/w (p< 0.05). The decrease
in size of nanoparticles upon increasing surfactant concentra-
tions may be due to the effective reduction in the interfacial
tension between the aqueous and the lipid phase, and thus
forming emulsion droplets of smaller size.24
Precirol SLN formulations modiﬁed with 2.5 and 5% w/w
Labrasoldid not show signiﬁcant differences (p> 0.05) in par-
ticle size, in comparison to those containing Labraﬁl. How-
ever, particle size of Precirol SLN formulations modiﬁed
with 10% w/w Labraﬁl exhibited smaller particle size
(p< 0.05) than those modiﬁed with 10% w/w Labrasol, prob-
ably due to the hydrophilicity of Labrasol, as explained
previously.1% w/w diﬂucortolone valerate loaded solid lipid nanoparticles.
PDIa Entrapment eﬃciency (%)a
0.251 ± 0.12 14.13 ± 1.90
0.308 ± 0.05 21.80 ± 2.90
0.374 ± 0.11 31.13 ± 2.40
0.298 ± 0.06 21.71 ± 3.58
0.338 ± 0.15 25.22 ± 0.29
0.252 ± 0.13 32.58 ± 3.50
ND ND
ND ND
ND ND
0.405 ± 0.07 31.87 ± 5.80
0.395 ± 0.08 31.64 ± 7.38
0.280 ± 0.12 45.79 ± 4.40
Figure 1 Scanning electron microscope micrograph showing the
surface of SLN18C.
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The mean EE% of the modiﬁed SLN formulations ranged
from 14.13 ± 1.9 to 45.79 ± 4.40% (Table 4). It is worth not-
ing that incorporation of 2.5% of the surfactants increased the
EE% of the drug in a range of 14–31% compared to 0% EE
for the non-modiﬁed formulations.
The EE% of DFV in Precirol SLN formulations showed a
gradual signiﬁcant increase (p< 0.05) upon increasing Labra-
sol concentration from 2.5 to 5 and to 10% w/w, (SLN12A,
SLN12B and SLN12C, respectively). Tristearin SLN formu-
lations modiﬁed with Labrasol at concentrations of 2.5, 5
and 10% w/w (SLN18A, SLN18B and SLN18C, respectively)
were not examined for their EE% because of their hard
consistency.
There was no signiﬁcant increase (p> 0.05) in the EE% of
DFV in either Precirol or Tristearin SLN formulations
upon increasing Labraﬁl concentration from 2.5 to 5% w/w
(SLN12D and SLN12E, SLN18D and SLN18E, respectively).
However, upon increasing Labraﬁl concentration to 10% w/
w, the EE% increased signiﬁcantly (p< 0.05), in both Pre-
cirol and Tristearin SLN formulations. This signiﬁcant
increase in the EE% may be attributed to the enhancement
of solubility of DFV in the lipid phase, which resulted in a
higher EE%.
The EE% of the drug in Tristearin SLNs modiﬁed with
2.5% w/w Labraﬁl (SLN18D) did not differ signiﬁcantly
(p> 0.05) from those containing Precirol (SLN12D) at the
same concentration of Labraﬁl. However, Tristearin SLN
formulations modiﬁed with 5 and 10% w/w Labraﬁl
(SLN18E and SLN18F, respectively) showed a signiﬁcantly
higher (p< 0.05) EE% compared to those containing Pre-
cirol (SLN12E and SLN12F). This might be due to the fact
that an increase in the alkyl chain length (C57 for Tristearin

versus C39 for Precirol
) increases the lipophilicity of the mole-
cule. Hence, the lipophilic surfactant (Labraﬁl) exhibited
higher miscibility in Tristearin than in Precirol, and, thus,
increasing the entrapment of the drug in the lipid phase.
The effect of Labrasol and Labraﬁl on the EE% of DFV
in SLN formulations in presence of Precirol as solid lipid wascompared which revealed that the EE% of the drug in SLN
formulations modiﬁed with 2.5% w/w Labraﬁl (SLN12D)
was signiﬁcantly (p< 0.05) higher than that containing 2.5%
w/w Labrasol (SLN12A). This might be due to the ability
of Labraﬁl with HLB value of 4, even at low concentration,
to solubilize the drug in the lipid phase more efﬁciently, being
more lipophilic than Labrasol of HLB value of 14. However,
no signiﬁcant difference in the EE% (p> 0.05) was recognized
at the higher concentrations of Labrasol and Labraﬁl (5 and
10% w/w).4. Conclusion
Semisolid formulations that have particle size in the nano-
range and adequate drug encapsulation efﬁciency, as well as,
viscoelastic properties, were prepared and characterized. It
was found that the use of lipid-based surfactants (Labrasol
or Labraﬁl) enhances the solubility of the lipophilic drug,
and thus, increase its entrapment efﬁciency in the SLNs.
Although the prior art reported that 30–50% lipid content is
needed in the one-step method to get the semisolid SLN for-
mulations, this study revealed that 10–20% w/w solid lipid
was enough to produce SLNs semisolid formulations. The
proper selection of type of lipids and surfactants, and their
incorporated concentrations, is critical in the formation of
SLN-based semisolid formulations that have the desirable
properties for potential topical applications.Declaration of interest
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